CURRENT PRINCIPLES AND TRENDS OF ATRIAL FIBRILLATION PHARMACOTHERAPY
https://doi.org/10.20996/1819-6446-2009-5-1-87-95
Abstract
Data on atrial fibrillation (AF) epidemiology and AF influence on the risk of cardiovascular complications are presented. Principles and tactics of AF therapy are discussed in accordance to evidence based medicine and European society of cardiology Guidelines. Algorithms for choice (on the basis of risk stratification) of different antiarrhythmic drugs and anticoagulants are described. Perspectives in improvement of efficacy and safety of AF therapy are reviewed.
About the Author
Yu. A. Bunin
Russian Medical Academy of Postgraduate Education
Russian Federation
Barrikadnaya ul. 1/2, Moscow, 123995
Russian Federation
Barrikadnaya ul. 1/2, Moscow, 123995
References
1. Fuster V, Rydn LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8(9):651-745.
2. Feinberg W.M., Blackshear J.L., Laupacis A. et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73.
3. Bialy D., Lehmann M.N., Schumacher D.N. et al. Hospitalization for arrhythmias in the United States: importance atrial fibrillation (abstract). J Am Coll Cardiol 1992;19:41A.
4. Hart R.G., Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32(3):803-8.
5. Benjamin E.J., Wolf P.A., D'Agostino R.B. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98(10):946-52.
6. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840-4.
7. Wyse D.G., Waldo A.L., DiMarco J.P. et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33.
8. Hagens V.E., Crijns H.F., Van Veldhusen D.J. et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the Rate control versus Electrical cardioversion (RACE) study. Am Heart J 2005;149(6):1106-11.
9. Roy D., Talajic M., Nattel S. et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;385(25):2667-77.
10. Steinberg J.S., Sadaniantz A., Kron J. et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109(16):1973-80.
11. Curtis A.B., Rich M.W. Atrial fibrillation in the elderly: mechanisms and management. Heart Rhythm 2007;4(12):1577-9.
12. Van Gelder I.C., Hemels M.E. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 2006;8(11):943-9.
13. Van Gelder I.C., Wyse D.G., Chandler M.L. et al. Does intensity of ratecontrol influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8(11):935- 42.
14. Lundström T., Rydn L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16(1):86-90.
15. Olgin J.E.. Zipes D.P. Specific arrhythmias: diagnosis and treatment. In Libby P., Bonow R.O., Mann D.L., Zipes D.P., eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed. Philadelphia: WB Saunders; 2005. p.803-863.
16. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501.
17. Finkle J.K., Plunkitt K., Kowey P.R. Pharmacologic management of atrial fibrillation. In Ganz L.I. Braunwald E., eds. Management of cardiac arrhythmias. Totowa, NJ: Humana Press; 2002. p.97-118.
18. Becker R.C., Fintel D.J., Green D. Antithrombotic therapy. Third edition New York: Professional communications; 2004.
19. Turpie A.G. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29(2):155-65.
20. Ostermayer S.H., Reisman M., Kramer P.H. et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46(1):9-14.
21. Bellandi F., Simonetti I., Leoncini M. et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88(6):640-5.
22. Сулимов В.А., Маколкин В.И., редакторы. Чреспищеводная электрическая стимуляция сердца. М.: "Медицина", 2001.
23. Бунин Ю.А., Федякина Л.Ф., Байрошевский П.А., Казанков Ю.Н. Комбинированная профилактическая антиаритмическая терапия этацизином и пропранололом пароксизмальной фибрилляции и трепетания предсердий. Материалы VII Российского национального конгресса "Человек и лекарство". Москва, 2000. С.124.
24. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 2000;15(1):41-53.
25. L'Allier P.L., Ducharme A., Keller P.F. et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44(1):159- 64.
26. Singh B.N., Aliot E. Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity? Eur Heart J Suppl 2007;9(Suppl G):G17-G25.
27. Бунин Ю.А., Федякина Л.Ф. Комбинированная профилактическая антиаритмическая фармакотерапия фибрилляции и трепетания предсердий. Российский кардиологический журнал 2006;(6):35-45.
Review
For citations:
Bunin Yu.A. CURRENT PRINCIPLES AND TRENDS OF ATRIAL FIBRILLATION PHARMACOTHERAPY. Rational Pharmacotherapy in Cardiology. 2009;5(1):87-95. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-1-87-95
Views:
712
Email this article 